S&P 500

5.537,02

0,51%

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
Canadá
TSX
Medicenna Therapeutics Corp (MDNA)
Medicenna Therapeutics Corp (MDNA) Notícias

MDNA

Medicenna Therapeutics (MDNA)

Medicenna Therapeutics Corp

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:TSX:MDNA

1 2 3 4 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
26/04/2024	09:16	PR Newswire (Canada)	L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - MDNA	TSX:MDNA	Medicenna Therapeutics Corp
26/04/2024	09:14	PR Newswire (Canada)	Canadian Investment Regulatory Organization Trade Resumption - MDNA	TSX:MDNA	Medicenna Therapeutics Corp
26/04/2024	09:09	PR Newswire (Canada)	Suspension de la négociation par l'Organisme canadien de réglementation des investissements - MDNA	TSX:MDNA	Medicenna Therapeutics Corp
26/04/2024	09:07	PR Newswire (Canada)	Canadian Investment Regulatory Organization Trading Halt - MDNA	TSX:MDNA	Medicenna Therapeutics Corp
11/06/2020	08:00	PR Newswire (Canada)	Medicenna to Present at Raymond James Human Healthcare Innovation Conference	TSX:MDNA	Medicenna Therapeutics Corp
29/05/2020	09:15	PR Newswire (US)	Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020	TSX:MDNA	Medicenna Therapeutics Corp
29/05/2020	09:05	PR Newswire (US)	Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020	TSX:MDNA	Medicenna Therapeutics Corp
15/05/2020	08:30	PR Newswire (US)	Medicenna Announces March 31, 2020 Year-End Results	TSX:MDNA	Medicenna Therapeutics Corp
04/05/2020	08:00	PR Newswire (Canada)	Medicenna Announces Upcoming Presentations at the ASCO Annual Meeting	TSX:MDNA	Medicenna Therapeutics Corp
15/04/2020	10:23	PR Newswire (Canada)	Medicenna Announces Full Exercise of Over-Allotment Option as Part of $40.25 Million Public Offering	TSX:MDNA	Medicenna Therapeutics Corp
25/03/2020	08:00	PR Newswire (US)	Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate Study	TSX:MDNA	Medicenna Therapeutics Corp
17/03/2020	10:14	PR Newswire (Canada)	Medicenna Announces Closing of Public Offering of $35 Million	TSX:MDNA	Medicenna Therapeutics Corp
12/03/2020	10:00	PR Newswire (Canada)	Medicenna Announces Intention to File Final Short Form Prospectus	TSX:MDNA	Medicenna Therapeutics Corp
04/03/2020	11:37	PR Newswire (Canada)	L'OCRCVM permet la reprise de la négociation - MDNA	TSX:MDNA	Medicenna Therapeutics Corp
04/03/2020	11:36	PR Newswire (Canada)	IIROC Trade Resumption - MDNA	TSX:MDNA	Medicenna Therapeutics Corp
04/03/2020	11:25	PR Newswire (Canada)	Medicenna Announces Pricing of $35 Million Overnight Marketed Offering of Common Shares	TSX:MDNA	Medicenna Therapeutics Corp
03/03/2020	19:14	PR Newswire (Canada)	Suspension de la négociation par l'OCRCVM - MDNA	TSX:MDNA	Medicenna Therapeutics Corp
03/03/2020	19:11	PR Newswire (Canada)	IIROC Trading Halt - MDNA	TSX:MDNA	Medicenna Therapeutics Corp
03/03/2020	18:35	PR Newswire (Canada)	Medicenna Announces Overnight Marketed Offering of Common Shares	TSX:MDNA	Medicenna Therapeutics Corp
13/02/2020	09:30	PR Newswire (US)	Medicenna Reports Third Quarter Fiscal 2020 Financial Results	TSX:MDNA	Medicenna Therapeutics Corp
13/01/2020	09:00	PR Newswire (US)	Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control Arm	TSX:MDNA	Medicenna Therapeutics Corp
08/01/2020	11:13	PR Newswire (US)	Medicenna Receives $1.3 Million Through Early Warrant Exercises	TSX:MDNA	Medicenna Therapeutics Corp
12/12/2019	10:00	PR Newswire (US)	Medicenna Presents Additional Encouraging Phase 2b Clinical Data at the Inaugural Glioblastoma Drug Development Annual Summit	TSX:MDNA	Medicenna Therapeutics Corp
09/12/2019	09:30	PR Newswire (US)	Medicenna Announces Presentation of the MDNA55 Clinical Trial at the Inaugural Glioblastoma Drug Development Annual Summit	TSX:MDNA	Medicenna Therapeutics Corp
25/11/2019	09:30	PR Newswire (US)	Medicenna Reports Promising Efficacy in Phase 2b MDNA55 Clinical Trial at the Society for Neuro-Oncology Annual Meeting	TSX:MDNA	Medicenna Therapeutics Corp
21/11/2019	10:00	PR Newswire (Canada)	Medicenna Reports Improved Drug Distribution of MDNA55 with Novel Delivery Technology in Phase 2b Recurrent Glioblastoma Clin...	TSX:MDNA	Medicenna Therapeutics Corp
20/11/2019	10:00	PR Newswire (US)	Medicenna To Host Key Opinion Leader Call Focused on Latest MDNA55 Recurrent Glioblastoma Phase 2b Clinical Study Results	TSX:MDNA	Medicenna Therapeutics Corp
18/11/2019	09:00	PR Newswire (Canada)	Medicenna to Host a Key Opinion Leader Symposium on MDNA55 for Treatment of Recurrent Glioblastoma	TSX:MDNA	Medicenna Therapeutics Corp
14/11/2019	09:00	PR Newswire (US)	Medicenna Announces Presentations on MDNA55 Recurrent Glioblastoma Clinical Trial at the Annual Meeting of the Society of Neu...	TSX:MDNA	Medicenna Therapeutics Corp
05/11/2019	10:00	PR Newswire (Canada)	Medicenna Reports Second Quarter Fiscal 2020 Financial Results	TSX:MDNA	Medicenna Therapeutics Corp